AbbVie [ABBV] vs Amgen [AMGN] Detailed Stock Comparison
AbbVie
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: AbbVie wins in 8 metrics, Amgen wins in 12 metrics, with 0 ties. Amgen appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | AbbVie | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 81.26 | 27.44 | Amgen |
| Price-to-Book Ratio | 234.48 | 26.10 | Amgen |
| Debt-to-Equity Ratio | 4,789.60 | 924.46 | Amgen |
| PEG Ratio | 15.54 | 14.58 | Amgen |
| EV/EBITDA | 14.54 | 13.39 | Amgen |
| Profit Margin (TTM) | 7.31% | 17.39% | Amgen |
| Operating Margin (TTM) | 30.43% | 28.73% | AbbVie |
| EBITDA Margin (TTM) | 30.43% | 28.73% | AbbVie |
| Return on Equity | 88.40% | 105.67% | Amgen |
| Return on Assets (TTM) | 8.34% | 7.04% | AbbVie |
| Free Cash Flow (TTM) | $17.83B | $10.39B | AbbVie |
| Dividend Yield | 3.44% | 3.20% | AbbVie |
| 1-Year Return | 1.02% | -9.11% | AbbVie |
| Price-to-Sales Ratio (TTM) | 5.86 | 4.75 | Amgen |
| Enterprise Value | $397.89B | $210.58B | AbbVie |
| EV/Revenue Ratio | 6.94 | 6.17 | Amgen |
| Gross Profit Margin (TTM) | 70.01% | 63.58% | AbbVie |
| Revenue per Share (TTM) | $32 | $63 | Amgen |
| Earnings per Share (Diluted) | $2.32 | $10.98 | Amgen |
| Beta (Stock Volatility) | 0.48 | 0.48 | Amgen |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
AbbVie vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| AbbVie | 1.43% | 2.20% | 3.02% | -1.18% | 9.11% | 6.56% |
| Amgen | 0.75% | -0.70% | 8.72% | 5.20% | 7.77% | 17.08% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| AbbVie | 1.02% | 38.53% | 105.79% | 178.67% | 479.45% | 479.45% |
| Amgen | -9.11% | 23.27% | 26.12% | 76.17% | 442.65% | 270.69% |
Performance & Financial Health Analysis: AbbVie vs Amgen
| Metric | ABBV | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $336.11B | $162.01B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 4,787,420 | 1,842,602 |
| 90 Day Avg. Volume | 6,195,300 | 2,429,634 |
| Last Close | $191.22 | $303.56 |
| 52 Week Range | $163.81 - $218.66 | $253.30 - $340.89 |
| % from 52W High | -12.55% | -10.95% |
| All-Time High | $218.66 (Mar 10, 2025) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -12.55% | -12.48% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.09% |
| Quarterly Earnings Growth | -0.06% | 0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.17% |
| Operating Margin (TTM) | 0.30% | 0.29% |
| Return on Equity (TTM) | 0.88% | 1.06% |
| Debt to Equity (MRQ) | 4,789.60 | 924.46 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.80 | $11.54 |
| Cash per Share (MRQ) | $2.93 | $16.38 |
| Operating Cash Flow (TTM) | $16.40B | $12.19B |
| Levered Free Cash Flow (TTM) | $16.94B | $13.09B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.44% | 3.20% |
| Last 12-Month Dividend | $6.38 | $9.26 |
Valuation & Enterprise Metrics Analysis: AbbVie vs Amgen
| Metric | ABBV | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 81.26 | 27.44 |
| Forward P/E | 15.54 | 14.58 |
| PEG Ratio | 15.54 | 14.58 |
| Price to Sales (TTM) | 5.86 | 4.75 |
| Price to Book (MRQ) | 234.48 | 26.10 |
| Market Capitalization | ||
| Market Capitalization | $336.11B | $162.01B |
| Enterprise Value | $397.89B | $210.58B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.94 | 6.17 |
| Enterprise to EBITDA | 14.54 | 13.39 |
| Risk & Other Metrics | ||
| Beta | 0.48 | 0.48 |
| Book Value per Share (MRQ) | $0.80 | $11.54 |
Financial Statements Comparison: AbbVie vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ABBV | AMGN |
|---|---|---|
| Revenue/Sales | $13.34B | $8.15B |
| Cost of Goods Sold | $4.00B | $2.97B |
| Gross Profit | $9.34B | $5.18B |
| Research & Development | $2.07B | $1.49B |
| Operating Income (EBIT) | $3.98B | $1.18B |
| EBITDA | $4.65B | $4.08B |
| Pre-Tax Income | $1.66B | $1.97B |
| Income Tax | $372.00M | $243.00M |
| Net Income (Profit) | $1.29B | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ABBV | AMGN |
|---|---|---|
| Cash & Equivalents | $5.18B | $8.81B |
| Total Current Assets | $27.68B | $26.93B |
| Total Current Liabilities | $36.40B | $23.01B |
| Long-Term Debt | $64.53B | $54.01B |
| Total Shareholders Equity | $1.46B | $6.21B |
| Retained Earnings | $-9.53B | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ABBV | AMGN |
|---|---|---|
| Operating Cash Flow | $2.26B | $1.71B |
| Capital Expenditures | $-235.00M | $-411.00M |
| Free Cash Flow | $1.40B | $980.00M |
| Debt Repayment | $-3.03B | $-2.50B |
| Common Stock Repurchase | $-961.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ABBV | AMGN |
|---|---|---|
| Shares Short | 15.61M | 14.70M |
| Short Ratio | 2.23 | 5.46 |
| Short % of Float | 0.01% | 0.03% |
| Average Daily Volume (10 Day) | 4,787,420 | 1,842,602 |
| Average Daily Volume (90 Day) | 6,195,300 | 2,429,634 |
| Shares Outstanding | 1.77B | 537.00M |
| Float Shares | 1.76B | 536.32M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.75% | 0.84% |
Dividend Analysis & Yield Comparison: AbbVie vs Amgen
| Metric | ABBV | AMGN |
|---|---|---|
| Last 12-Month Dividend | $6.38 | $9.26 |
| Last 12-Month Dividend Yield | 3.44% | 3.20% |
| 3-Year Avg Annual Dividend | $6.07 | $8.72 |
| 3-Year Avg Dividend Yield | 0.95% | 0.79% |
| 3-Year Total Dividends | $18.22 | $26.16 |
| Ex-Dividend Date | Apr 15, 2025 | May 16, 2025 |